ProMIS Neurosciences announces results presented at the 13th International Conference on Alzheimer's and Parkinson's diseases held in Vienna, Austria
(Thomson Reuters ONE) -
TORONTO, April 12, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences ("ProMIS" or
the "Company"), a company focused on the discovery and development of precision
treatments for neurodegenerative diseases, today announces results of its recent
therapeutic developments presented at the 13(th) International Conference on
Alzheimer's (AD) and Parkinson's diseases held in Vienna, Austria, from March
29 to April 2nd. This year's conference was devoted to mechanisms, clinical
strategies and promising treatments of neurodegenerative diseases.
"Results presented at the 13(th) International AD/PD conference confirmed ProMIS
monoclonal antibodies (mAbs) selectively target five distinct epitopes on
misfolded strains of toxic Amyloid beta (Aß), without targeting Aß monomer or
plaque", stated Dr. Elliot Goldstein, ProMIS President and CEO. "Prior AD
clinical trials with mAbs targeting monomer (e.g. solanezumab) have been
ineffective, due to target distraction, whereas mAbs targeting plaque (e.g.
aducanumab) are associated with the dose limiting toxicity of brain swelling. By
specifically targeting only the toxic forms of Aß, we anticipate ProMIS mAbs
will demonstrate a best in class product profile with respect to both efficacy
and tolerabilty".
ProMIS' communication at the Conference, entitled Rational generation
of Aß oligomer-specific antibodies through computational identification of
conformational epitopes, was an oral presentation and poster authored by Dr.
Ebrima Gibbs (et al.), from the laboratory of ProMIS Chief Scientific Officer,
Dr. Neil Cashman. The authors used the Company's two proprietary computational
algorithms (ProMIS((TM)) and Collective Coordinates) to predict structurally
integral misfolding of Aß and the resulting five disease specific epitopes
(targets for antibodies). ProMIS mAbs raised against each of these targets
showed:
* Preferential binding to synthetic Aß oligomers and negligible binding to
monomers;
* Inhibition of Aß oligomer propagation;
* Binding to naturally-occuring soluble Aß oligomers in AD brain tissue and
CSF, with no detectable reactivity to plaques in cadaveric AD brain tissue;
* Protection against Aß neurotoxicity in vitro.
In addition, the Company's lead mAb product PMN310, improved cognitive function
in a preclinical animal model evaluating short term memory retention (dual
object recognition test).
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision
medicine therapeutics for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platforms -- ProMIS((TM)) and Collective Coordinates --
to predict novel targets known as Disease Specific Epitopes (DSEs) on the
molecular surface of misfolded proteins. Using this unique "precision medicine"
approach, ProMIS Neurosciences is developing novel antibody therapeutics and
specific companion diagnostics for Alzheimer's disease and ALS. The company has
also developed two proprietary technologies to specifically identify very low
levels of misfolded proteins in a biological sample. In addition, ProMIS
Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to
misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody
therapeutics against this target.
The information in this release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to it
as well as other factors. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
cbealamaro(at)streetwisereports.com
or contact
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 536053
Anzahl Zeichen: 5865
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences announces results presented at the 13th International Conference on Alzheimer's and Parkinson's diseases held in Vienna, Austria"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
